Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study
These data highlight the unmet clinical needs of patients with HER2-low mBC by characterizing the treatment patterns and poor outcomes in this population on the current standard of care.
Authors
- Kyle Dunton (ORCID: https://orcid.org/0000-0002-1200-6755)
- Danalyn Byng (ORCID: https://orcid.org/0000-0002-8754-0530)
- Shannon Hunter (ORCID: https://orcid.org/0000-0001-9435-7737)
- Shanu Modi (ORCID: https://orcid.org/0000-0001-6427-7373)
- William Jacot (ORCID: https://orcid.org/0000-0001-7834-061X)
- Z. Mbanya
- Suyuan Zhang (ORCID: https://orcid.org/0000-0002-5476-0748)
- Yan Xiong (ORCID: https://orcid.org/0000-0002-1237-3010)
- Alessandria Strübing
Institutions
- AstraZeneca (United Kingdom) (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Inserm (FR)
- Daiichi Sankyo (Germany) (DE)
- Université de Montpellier (FR)
- Daiichi Sankyo (United Kingdom) (GB)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Daiichi Sankyo (United States) (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1007/s10549-025-07649-y
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- AstraZeneca
- Daiichi Sankyo Europe